Related Experiment Video
Updated: Feb 14, 2026
In Vitro Assays to Evaluate the Migration, Invasion, and Proliferation of Immortalized Human First-trimester Trophoblast Cell Lines
Published on: March 5, 2019
New cGMP analogues restrain proliferation and migration of melanoma cells
Eleonora Vighi1, Andreas Rentsch2, Philipp Henning3
1University of Modena and Reggio Emilia, Department of Life Sciences, 41125 Modena, Italy.
Abstract:
Melanoma is one of the most aggressive cancers and displays high resistance to conventional chemotherapy underlining the need for new therapeutic strategies. The cGMP/PKG signaling pathway was detected in melanoma cells and shown to reduce migration, proliferation and to increase apoptosis in different cancer types. In this study, we evaluated the effects on cell viability, cell death, proliferation and migration of novel dimeric cGMP analogues in two melanoma cell lines (MNT1 and SkMel28). These new dimeric cGMP analogues, by activating PKG with limited effects on PKA, significantly reduced proliferation, migration and increased cell death. No decrease in cell viability was observed in non-tumor cells suggesting a tumor-specific effect. These effects observed in melanoma are possibly mediated by PKG2 activation based on the decreased toxic effects in tumor cell lines not expressing PKG2. Finally, PKG-associated phosphorylation of vasodilator-stimulated-phosphoprotein (VASP), linked to cell death, proliferation and migration was found increased and with a change of subcellular localization. Increased phosphorylation of RhoA induced by activation of PKG may also contribute to reduced migration ability of the SkMel28 melanoma cell line when treated with cGMP analogues. These findings suggest that the cGMP/PKG pathway can be envisaged as a therapeutic target of novel dimeric cGMP analogues for the treatment of melanoma.
Insights
Novel dimeric cyclic GMP (cGMP) analogues effectively target melanoma by activating the protein kinase G (PKG) pathway. These analogues reduce cancer cell proliferation and migration while increasing cell death, offering a promising new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Melanoma is an aggressive cancer with high resistance to chemotherapy, necessitating novel therapeutic approaches.
- The cyclic GMP (cGMP)/protein kinase G (PKG) signaling pathway has shown potential in reducing cancer cell migration and proliferation and increasing apoptosis in various cancer types.
Purpose of the Study:
- To evaluate the efficacy of novel dimeric cGMP analogues in melanoma treatment.
- To investigate the effects of these analogues on cell viability, death, proliferation, and migration in melanoma cell lines.
Main Methods:
- Treatment of MNT1 and SkMel28 melanoma cell lines with novel dimeric cGMP analogues.
- Assessment of cell viability, apoptosis, proliferation, and migration.
- Analysis of PKG and PKA activation.
- Investigation of VASP and RhoA phosphorylation and localization.
Main Results:
- Dimeric cGMP analogues significantly reduced melanoma cell proliferation and migration while increasing cell death.
- These effects were specific to tumor cells, with no observed decrease in non-tumor cell viability.
- PKG2 activation appeared to mediate the anti-melanoma effects.
- PKG activation led to increased VASP phosphorylation and altered subcellular localization, and increased RhoA phosphorylation, contributing to reduced migration.
Conclusions:
- The cGMP/PKG pathway is a viable therapeutic target for melanoma.
- Novel dimeric cGMP analogues demonstrate significant anti-melanoma activity through PKG activation.
- These findings support the development of cGMP analogues as a new class of melanoma therapeutics.
Related Concept Videos
01:19Cell Migration
01:09Cell Migration
02:36Cells Coordinate Growth and Proliferation
02:23Abnormal Proliferation
01:35Cancer Cell Migration through Invadopodia
01:21Chemotaxis and Direction of Cell Migration